The incidence of secondary outcomes was significantly lower in the rosuvastatin group compared with control group ( 2.7 % vs. 5.3 % , P = 0.049 ) in the overall cohort , but it was similar between the patients with MCV ( 2.0 % vs. 4.2 % , P = 0.081 ) or HCV ( 5.1 % vs. 8.8 % , P = 0.273 ) .